12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Company News  |  Deals

ConfometRx, UCB deal

UCB and structural biology company ConfometRx partnered to research GPCR modulation to discover new therapies for neuroscience indications. UCB said the deal aims to obtain the crystal structures of GPCR targets...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >